Table 1.

Current FDA approved biologic therapies for the treatment of Crohn’s disease

Class	Name	Brand Name	Reference / Biosimilar	Route of Administration	Dosing		Suggested Trough level
					Induction	Maintenance
Anti-TNFa	Infliximab	Remicade	Reference	IV	5 mg/kg at week 0, 2, and 6	5 mg/kg every 8 weeks	≥ 5 ug/mL
	Infliximabdyyb	Inflectra	Biosimilar
	Infliximabqbtx	Ixifi
	Infliximababda	Renflexis
	Adalimumab	Humira	Reference	Subq	160 mg at week 0, 80 mg at week 2	40 mg every 2 weeks	≥ 7.5 ug/mL
	Adalimumabatto	Amjevita	Biosimilar
	Adalimumabadbm	Cyltezo
	Adalimumabadaz	Hyrimoz
	Certolizumab Pegol	Cimzia	Reference	Subq	400 mg at week 0, 2 and 4	400 mg every 4 weeks	≥ 20 ug/mL
Anti-α4 integrin	Natalizumab	Tysabri	Reference	IV	300 mg every 4 weeks	300 mg every 4 weeks	Not determined
Anti-α4β7 integrin	Vedolizumab	Entyvio	Reference	IV	300 mg at week 0, 2, and 6	300 mg every 8 weeks	Not determined
Anti-IL12/23	Ustekinumab	Stelara	Reference	IV for induction, Subq for maintenance	< 55 mg = 260 mg; 55-85 mg = 390 mg; >85 mg = 520 mg	90 mg every 8 weeks	Not Determined